导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 4.16% | 1458/4773 |
| 近一周 | -1.20% | 1806/5465 |
| 近一月 | -8.19% | 4814/5421 |
| 近一季 | -18.15% | 4699/5231 |
| 近半年 | -0.47% | 1488/4920 |
| 近一年 | 8.28% | 1350/4394 |
| 近两年 | 111.95% | 507/2954 |
| 近三年 | 64.45% | 419/2253 |
| 成立以来 | 82.57% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-0.49% 1823/4961 |
34.97% 934/5312 |
- - |
- - |
| 2025 | 48.36% 532/4813 |
-1.70% 2748/3635 |
3.13% 1146/4076 |
47.40% 464/4524 |
-0.72% 2611/4813 |
| 2024 | 12.49% 1241/3463 |
-4.49% 1680/2808 |
-6.34% 1916/3014 |
27.45% 221/3129 |
-1.34% 1662/3463 |
| 2023 | -18.50% 1810/2656 |
1.87% 1491/2280 |
-6.92% 1739/2385 |
-9.13% 1779/2515 |
-5.42% 1350/2655 |
| 2022 | -28.16% 1535/2207 |
-19.14% 1435/1919 |
5.58% 866/2016 |
-17.70% 1634/2113 |
2.24% 1009/2208 |
| 2021 | 11.23% 405/1822 |
-6.64% 1025/1255 |
24.81% 104/1330 |
-6.40% 924/1466 |
1.99% 729/1822 |
| 2020 | 59.69% 126/1250 |
2.95% 129/1028 |
28.74% 95/1067 |
5.41% 919/1164 |
14.30% 285/1184 |
| 2019 | 39.79% 271/1092 |
31.89% 183/739 |
-9.85% 699/788 |
7.17% 100/850 |
9.70% 207/918 |
| 2018 | -26.25% 376/834 |
- - |
-14.06% 479/631 |
-10.93% 553/660 |
-10.74% 219/682 |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 易方达创业板ETF联接C VS. 长安沪深300非周期A(740101) |